Diurnal Group PLC Notice of Results (4573J)
12 September 2016 - 4:01PM
UK Regulatory
TIDMDNL
RNS Number : 4573J
Diurnal Group PLC
12 September 2016
12 September 2016
Diurnal Group plc
("Diurnal" or the "Company")
Notice of Final Results
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, will announce its financial results for the year ended 30
June 2016 on Wednesday, 12 October 2016.
Please further information, please visit www.diurnal.co.uk or
contact:
Diurnal Group plc +44 (0)20 3727 1000
Martin Whitaker, CEO
Ian Ardill, CFO
Numis Securities Ltd +44 (0)20 7260 1000
Nominated Adviser: Michael
Meade, Freddie Barnfield,
Paul Gillam
Corporate Broking: James
Black
FTI Consulting + 44 (0)20 3727 1000
Simon Conway
Victoria Foster Mitchell
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company
developing high quality products for the global market for the
life-long treatment of chronic endocrine conditions, including
Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its
expertise and innovative research activities focus on
circadian-based endocrinology to yield novel product candidates in
the rare and chronic endocrine disease arena.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLLFFLAVIAIIR
(END) Dow Jones Newswires
September 12, 2016 02:01 ET (06:01 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2024 to May 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Diurnal Group Plc (London Stock Exchange): 0 recent articles
More Diurnal Grp News Articles